Table 2.
Mutation | na (%) | Nevirapine univariate |
Efavirenz univariate |
Etravirine |
|||||
---|---|---|---|---|---|---|---|---|---|
univariate |
multivariateb |
||||||||
relative change (95% CI) | P value | relative change (95% CI) | P value | relative change (95% CI) | P value | relative change (95% CI) | P value | ||
No. of TAMs | |||||||||
0 | 8 (23) | 1.0 | 0.78 | 1.0 | 0.17 | 1.0 | 0.01 | 1.0 | <0.001 |
1–2 | 9 (26) | 0.87 (0.37, 2.03) | 0.62 (0.37, 1.06) | 0.51 (0.33, 0.80) | 0.47 (0.30, 0.71) | ||||
≥3 | 18 (51) | 0.77 (0.37, 1.62) | 0.69 (0.44, 1.10) | 0.60 (0.41, 0.88) | 0.49 (0.34, 0.71) | ||||
K65R | 1 (3) | 1.04 (0.18, 6.03) | 0.96 | 1.13 (0.36, 3.54) | 0.83 | 0.99 (0.35, 2.82) | 0.99 | 0.32 (0.12, 0.84) | 0.02 |
69ins | 1 (3) | 0.53 (0.09, 3.04) | 0.47 | 0.66 (0.21, 2.04) | 0.45 | 0.97 (0.34, 2.76) | 0.96 | ||
L74V | 1 (3) | 1.31 (0.23, 7.57) | 0.75 | 1.34 (0.43, 4.20) | 0.60 | 1.28 (0.45, 3.61) | 0.64 | ||
Y115F | 4 (11) | 0.89 (0.35, 2.22) | 0.79 | 1.10 (0.60, 2.00) | 0.75 | 0.68 (0.40, 1.15) | 0.15 | 0.62 (0.38, 1.00) | 0.05 |
M184V | 31 (89) | 0.90 (0.36, 2.24) | 0.81 | 0.63 (0.36, 1.13) | 0.12 | 0.45 (0.28, 0.73) | 0.002 | ||
N348I | 5 (14) | 1.10 (0.48, 2.53) | 0.82 | 1.00 (0.58, 1.73) | 0.99 | 1.30 (0.80, 2.12) | 0.28 | 1.77 (1.14, 2.77) | 0.01 |
A360IV | 3 (9) | 2.09 (0.76, 5.75) | 0.15 | 1.16 (0.59, 2.30) | 0.65 | 1.01 (0.54, 1.88) | 0.97 | ||
E399D | 1 (3) | 0.76 (0.13, 4.38) | 0.75 | 0.59 (0.19, 1.83) | 0.35 | 0.65 (0.23, 1.82) | 0.40 |
aNumber of patients in whom a mutation was observed at week 96 that was not observed at week 0.
bA backwards stepwise approach was used, starting with all variables (see the Methods section).